课题基金 / 基金详情

REGULATION OF INTRACELLULAR CALCIUM IN PARATHYROID CELLS

REGULATION OF INTRACELLULAR CALCIUM IN PARATHYROID CELLS
甲状旁腺细胞内钙的调节
批准号:
2142989
负责人:
DOLORES M. SHOBACK
金额:
$13.99万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-06-01 至 1999-03-31

项目摘要

项目成果

DOLORES M. SHOBACK的其他基金

相似基金

相关文献

中文摘要
翻译
甲状旁腺素的分泌受细胞外(EC)[Ca~(2+)]变化控制。 高钙对甲状旁腺激素释放有抑制作用,低钙对甲状旁腺素的释放有最大刺激作用。 EC[Ca~(2+)]也通过对Pre-Pre的影响来调节PTH的生物合成。 ProPTH mRNA水平和PTH基因转录水平。后一种影响是 可能在慢性适应血钙变化中起关键作用 活着。钙离子被认为与最近发现的一种膜钙离子相互作用 与磷脂酶C激活、1,4,5-InsP3形成偶联的传感器, [Ca~(2+)]i持续升高,最终抑制甲状旁腺素 分泌物。甲状旁腺细胞持续的细胞内钙反应 需要EC Ca~(2+),我们推测,这是膜开放的结果 钙离子通道。关于药理方面的信息很少, 钙离子内流途径的生化或分子特性 甲状旁腺细胞。通过全细胞膜片钳技术,我们记录到了钙离子 电流对电压不敏感,对阳离子有选择性,并被 La3+和Gd3+。在微量荧光法研究中,Gd3+显著地还原 细胞内Ca~(2+)对高EC[Ca~(2+)]的反应 Gd3+-阻滞性电流在调节钙内流中的重要性。vt.在.的基础上 进一步分析,钙电流由2个组分组成。一 分量是其电导依赖于电压不敏感的电流 [Ca~(2+)]变化。这一电流被二氢吡啶阻断 钙通道拮抗剂,并受蛋白激酶A的负性调节。 其他电流成分是电压依赖的,由蛋白质调节 提出的研究有四个目的:(1)研究KC的作用。 钙离子浓度持续升高在甲状旁腺激素慢性抑制中的作用 通过测量甲状旁腺激素释放和前甲状旁腺激素mRNA的分泌和生物合成 与选择性诱导瞬变的药物孵育的细胞中的水平 或一过性加持续的[Ca~(2+)]i升高;(2)定义 甲状旁腺细胞内钙离子通道的特性及其评价 通过磷酸化和鸟苷酸的调节;(3)评估 钙电流对[Ca~(2+)]i持续升高的贡献及其意义 在高钙诱导的甲状旁腺素分泌/生物合成抑制中的作用 使用通道激动剂和拮抗剂;以及(4)从 甲状旁腺基因文库,编码二氢吡啶敏感的钙离子 通道,在非洲爪哇卵母细胞中表达,并确定这是否 通道可以耦合到钙离子传感器。甲状旁腺细胞的钙通道 可以作为关键机制,用于转换由 钙传感器与细胞内钙离子的相互作用。这些渠道可能会 有助于长期适应钙缺乏状态或慢性 体内的高钙血症条件。
英文摘要
PTH secretion is controlled by changes in the extracellular (EC) [Ca2+]. High EC Ca2+ inhibits, and low EC Ca2+ maximally stimulates PTH release. The EC [Ca2+] also modulates PTH biosynthesis through effects on pre- proPTH mRNA levels and PTH gene transcription. These latter effects are likely to be crucial in the chronic adaptation to changes in serum Ca2+ in vivo. Ca2+ is thought to interact with a recently identified membrane Ca2+ sensor which couples to phospholipase C activation, 1,4,5-InsP3 formation, sustained increases in [Ca2+]i, and eventually, to the inhibition of PTH secretion. Sustained intracellular Ca2+ responses in parathyroid cells require EC Ca2+ and, we hypothesize, result from the opening of membrane Ca2+ Channels. Little information is available on the pharmacologic, biochemical, or molecular properties of Ca2+ influx pathways in parathyroid cells. By whole-cell patch-clamping, we have recorded Ca2+ currents which are voltage-insensitive, cation-selective and blocked by La3+ and Gd3+. In microflurimetry studies, Gd3+ markedly reduces intracellular Ca2+ responses to high EC [Ca2+], underscoring the potential importance of Gd3+-blockable Currents in mediating Ca2+ influx. Upon further analysis, the Ca2+ currents are comprised of 2 components. One component is a voltage-insensitive current whose conductance is dependent on changes in the EC [Ca2+]. This current is blocked by dihydropyridine Ca2+ channel antagonists and negatively modulated by protein kinase A. The other current component is voltage-dependent and regulated by protein kinase C. The studies proposed have 4 aims: (1) to investigate the role of sustained increases in [Ca2+]i in mediating chronic suppression of PTH secretion and biosynthesis, by measuring PTH release and pre-proPTH mRNA levels in cells incubated with agents which selectively induce transient or transient plus sustained increases in [Ca2+]i; (2) to define the properties of Ca2+ channels in parathyroid cells and assess their regulation by phosphorylation and guanyl nucleotides; (3) to assess the contribution of Ca2+ currents to sustained increases in [Ca2+]i and their role in high EC Ca2+-induced suppression of PTH secretion/biosynthesis, using channel agonists and antagonists; and (4) to isolate a cDNA from a parathyroid cDNA library, which encodes a dihydropyridine-sensitive Ca2+ channel, as expressed in Xenopus oocytes, and to determine whether this channel can couple to the Ca2+ sensor. Ca2+ channels in parathyroid cells may serve as a key mechanism for transducing signals initiated by the interaction of EC Ca2+ with the Ca2+ sensor. These channels are likely to contribute to the longterm adaptation to Ca2+ deficiency states or chronic hypercalcemic conditions in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Combination Therapy for Osteoporosis in Men
Novel Combination Therapy for Osteoporosis in Men
Novel Combination Therapy for Osteoporosis in Men
Novel Combination Therapy for Osteoporosis in Men
海外基金